Direkt zum Inhalt
Merck

V-902

Supelco

Vardenafil dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

1 ML
CHF 206.00

CHF 206.00


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
1 ML
CHF 206.00

About This Item

Empirische Formel (Hill-System):
C23H32N6O4S·2HCl
CAS-Nummer:
Molekulargewicht:
561.52
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

CHF 206.00


Check Cart for Availability

Bulk-Bestellung anfordern

Qualität

certified reference material

Qualitätsniveau

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol (as free base)

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

pharmaceutical (small molecule)

Format

single component solution

Lagertemp.

−20°C

SMILES String

O=C(C1=C(C)N=C(CCC)N1N2)N=C2C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC.Cl.Cl

InChI

1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

InChIKey

NOIHTGOGFDFCBN-UHFFFAOYSA-N

Angaben zum Gen

human ... PDE5A(8654)

Allgemeine Beschreibung

Vardenafil, a phosphodiesterase inhibitor, is used to treat erectile dysfunction. This Snap-N-Spike® reference solution is applicable for use in urine drug testing, clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Vardenafil is sold under the trade names Levitra® and Staxyn®.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Levitra is a registered trademark of Bayer Aktiengesellschaft
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Staxyn is a registered trademark of Bayer Aktiengesellschaft

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes,Central nervous system

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 1

1 of 1

Kenneth Beer
Journal of drugs in dermatology : JDD, 11(12), 1494-1495 (2013-02-05)
Eruptions from drugs are among the most frequently reported adverse events. The most frequent etiologic agents include antibiotics and nonsteroidal anti-inflammatory agents. These eruptions are also a frequent source of visits to dermatology of!ces. Many of the inciting agents are
Daniel J Mans et al.
Journal of pharmaceutical and biomedical analysis, 75, 153-157 (2012-12-25)
Ion mobility spectrometry was used as a rapid screening tool for the detection of acetildenafils, sildenafils and avanafil within adulterated herbal supplement matrices. Acetildenafils show a tendency for partial fragmentation during the desorption/ionization process affording two peaks in the ion
[New Levitra in the treatment of erectile dysfunction].
A L Vertkin et al.
Urologiia (Moscow, Russia : 1999), (6)(6), 100-102 (2013-02-06)
Christoph Zenzmaier et al.
Endocrinology, 153(11), 5546-5555 (2012-09-06)
Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed to evaluate the potential of the PDE5 inhibitor vardenafil
S I Gamidov et al.
Urologiia (Moscow, Russia : 1999), (3)(3), 102-104 (2013-08-31)
Due to high efficiency, prompt action and low incidence of side effects, phosphodiesterase type 5 inhibitors are the drugs of first choice in the treatment of erectile dysfunction (ED). One of the most widely used drugs in this group currently

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.